Bangalore, Karnataka, India
"Global Biotech Opportunities With-in India and Overseas" was one of the topics discussed on day 2 of Bangalore Bio 2008. The panel discussion chaired by Dr. K. K. Narayanan - President, ABLE and the speakers were, Dr. D. A. Prasanna - Vice Chairman & Founder, Manipal AcuNova Ltd, Dr. Amanda Caples Director - Biotechnology, Department of Innovation, Industry & Regional Development State Govt. of Victoria, Australia, Dr. Emmanuelle Voisin - Director, Voisin Consulting, France, Mr. David Hawkins - Sector Specialist, UK Trade & Investment, UK and Mr. K.R.K. Reddy - Additional Secretary & Director Of Biotechnology, Industries and Commerce Department, Government of Andhra Pradesh.
As Biopharma accounts for 71% of total Biotech market in India (2006-07), there is lot of scope for those who are working on Biosimilars. There are opportunities for Indian companies to move ahead in the value chain in the development of Biosimilars for domestic market as well as for the European and Australian partners.
K R K Reddy, explained how Genome Valley and other biotech platforms in the state played facilitating role for the new industries to take birth and grow. According to Reddy, the biotech clusters in Hyderabad, Bangalore, Mumbai and Delhi are capable of paving the way for more new business opportunities with international partnerships.
"There are many opportunities for Indian companies to forge collaborations with their peers in East Europe, as they share common goals," said Emmanuel Voisin. "Europe is the preferred target for Biosimilars," she added.
Biosimilar is a product of biological source and similar to a biological medicinal product, but different from a generic product.
India is still a low cost destination for drug development and clinical trials, but this will not remain as a phenomenon forever, according to Dr K K Narayanan.
"India can play a key role in bringing new drugs faster to the market in domestic market as well as International market," said Dr D A Prasanna. "Indian companies can play a key role in the Phase I and Phase II trials, which usually take six to eight years," he said.
"Indian Government has some serious concerns about the phase I clinical trials, particularly when a country does not want to conduct trails in their own homeland but want to do here. To avoid such unpleasant and unethical situations, Indian companies can focus on concurrent development, co-development, and repeated phase I clinical trials." said Prasanna.
Source: Bangalore Bio 2008 (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.